Last reviewed · How we verify

NCT05539313

Examination of Fibrillation Atria Using Magnetic Resonance Imaging and Endocardial High-density Mapping

Status unknown Last updated 15 February 2023
What this trial tests

trial testing High-density mapping in Atrial Fibrillation in 50 participants. Status unknown.

Timeline
1 November 2022
Primary endpoint
1 December 2024
1 December 2024

Quick facts

Lead sponsorCharles University, Czech Republic
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date1 November 2022
Primary completion1 December 2024
Estimated completion1 December 2024
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Charles University, Czech Republic

Who can join

Adults 18 to 75, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cather ablation of non-paroxysmal atrial fibrillation is less effective compared to paroxysmal atrial fibrillation. Therefore, new techniques have been developed, such as high-density mapping to determine areas of focal and rotational activities. The aim is to assess the clinical efficacy of ablation focal and rotational activities, and to assess the relation between the areas of focal and rotational activities with fibrosis of both atria assessed using magnetic resonance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Charles University, Czech Republic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05539313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing